Home / Tag Archives: Nektar Therapeutics

Tag Archives: Nektar Therapeutics

Healthcare Updates: Nektar Therapeutics (NASDAQ: NKTR)

Nektar Therapeutics (NASDAQ: NKTR) recently declared positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate that treatment with NKTR-358 induces profound regulatory T cell effects and suppresses inflammation in multiple preclinical models. The data were highlighted in an oral presentation at the …

Read More »